
Sign up to save your podcasts
Or


In this episode of The First Fill, we will review two recent new drug approvals, gepotidacin for UTI and lenacapavir for treatment and prevention of HIV. You'll hear about outcomes from clinical trials and patient counseling points for the new agents.
Each month, APhA will release two podcast episodes offering a fresh dose of education highlights, practice pearls, and insights to inform your pharmacy practice and advance patient care. Listen to new episodes at your convenience! Both members and nonmembers can log into their APhA pharmacist.com Learning Library account to successfully complete a short assessment at the end of each month to earn 0.5 hours of CE credits (.05 CEU).
Tune in now on our website or subscribe via YouTube, Spotify, or Apple Podcasts.
Disclaimer: The content is intended for informational purposes only and should not be considered or taken as medical advice. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or positions of any entities they represent or its employees.
By American Pharmacists Association (APhA)4.1
1111 ratings
In this episode of The First Fill, we will review two recent new drug approvals, gepotidacin for UTI and lenacapavir for treatment and prevention of HIV. You'll hear about outcomes from clinical trials and patient counseling points for the new agents.
Each month, APhA will release two podcast episodes offering a fresh dose of education highlights, practice pearls, and insights to inform your pharmacy practice and advance patient care. Listen to new episodes at your convenience! Both members and nonmembers can log into their APhA pharmacist.com Learning Library account to successfully complete a short assessment at the end of each month to earn 0.5 hours of CE credits (.05 CEU).
Tune in now on our website or subscribe via YouTube, Spotify, or Apple Podcasts.
Disclaimer: The content is intended for informational purposes only and should not be considered or taken as medical advice. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or positions of any entities they represent or its employees.

38,860 Listeners

6,245 Listeners

101 Listeners

258 Listeners

74,762 Listeners

3,361 Listeners

1,457 Listeners

16,923 Listeners

732 Listeners

25,346 Listeners

317 Listeners

619 Listeners

20,020 Listeners

10,246 Listeners

0 Listeners